Dec'04 | Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
FCF to Net Income | 99.9% | 88.6% | 77.3% | 72.0% | 51.4% | 116.8% | 75.2% | 52.8% | 30.2% | 163.5% | 345.6% | 17.5% | 51.5% | 87.9% | 62.6% | 32.9% | 56.0% | (1,420.0%) | 289.4% | 95.2% |
Discover the top 20 best undervalued stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued large-cap growth stocks to buy for Feb 2025, listed on the Nasdaq or NYSE.
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Feb 2025.
As of today, Microsoft Corp's last 12-month FCF to Net Income is 88.5%, based on the financial report for Dec 31, 2024 (Q4 2024). The average annual FCF to Net Income for AstraZeneca PLC have been (4.6%) over the past three years, and 15.7% over the past five years.
As of today, AstraZeneca PLC's FCF to Net Income is 88.5%, which is lower than industry median of 88.5%. It indicates that AstraZeneca PLC's FCF to Net Income is Bad.